Parabilis Medicines is exploding higher following the announcement on October 19 that the company will present updated clinical data for its drug candidate zolucatetide at the ESMO Congress 2026. This presentation will feature results from an ongoing Phase 1/2 trial in patients with desmoid tumors, specifically highlighting a dose optimization arm intended to guide the design of a future Phase 3 registrational trial. While the broader biotechnology sector remains active with various regulatory updates and clinical presentations from peers, the specific focus on Parabilis's upcoming data webcast scheduled for October 24 serves as the primary driver for today's move.